Tirzepatide and Psoriasis: What TOGETHER-PsO Found

A randomized 2026 trial found that adding tirzepatide to ixekizumab improved combined skin-clearance and weight outcomes in adults with moderate to severe plaque psoriasis and overweight or obesity. This is meaningful clinical evidence for a particular combination in a particular population. It does not establish tirzepatide as a replacement for psoriasis treatment.¹

If you have both psoriasis and excess weight, the useful question is whether treating the two conditions together could fit your care plan. The answer should involve the clinician managing your skin disease and the clinician prescribing weight treatment.

What TOGETHER-PsO compared

The phase 3b study randomized 274 adults with obesity, or overweight plus at least one weight-related comorbidity, at 72 U.S. sites to ixekizumab plus tirzepatide or ixekizumab alone. Both groups also received diet and exercise guidance. The trial was open label, so participants and investigators knew the assigned treatment. The published analysis assessed the primary endpoint at week 36 within a 52-week study.¹

Everyone in this comparison received ixekizumab. There was no tirzepatide-only group. Consequently, this trial cannot answer whether tirzepatide by itself would control plaque psoriasis or whether another biologic would produce the same combination benefit.

The main result combined two goals

At week 36, 27.1% of people assigned the combination simultaneously achieved complete skin clearance on the Psoriasis Area and Severity Index, called PASI 100, and at least 10% weight reduction. The corresponding proportion with ixekizumab alone was 5.8%.¹

Because this endpoint requires both outcomes, it should not be described simply as a skin-clearance rate. Adding a weight treatment can improve a combined endpoint partly through its weight effect. A reader deciding about psoriasis care needs to examine the separate skin outcome too.

What happened to skin clearance alone?

The reported PASI 100 proportions were 40.6% with the combination and 29.0% with ixekizumab alone. The reported adjusted risk difference was 11.6 percentage points (95% confidence interval, 0.3 to 22.9), a between-group difference rather than a 11.6% relative increase. This suggests an additional skin benefit in the studied population. It does not identify how much was mediated by weight reduction versus another biological pathway, and it does not establish that every patient will improve.¹

The study should therefore support a coordinated treatment discussion, rather than a promise that an obesity medicine will clear psoriasis. Changes in your existing biologic, topical treatment or follow-up schedule still need the clinician managing that condition.

A correction was checked

JAMA Dermatology published a correction to Table 2. It changed variability labels for PASI changes from standard deviation to standard error and clarified that metabolic endpoints used standard error. The notice describes labeling corrections; it does not announce replacement percentages for the outcomes summarized above.²

This matters because standard error and standard deviation describe different things. A smaller standard error should not be mistaken for proof that individual patients all had similar responses. When reading the table, use the corrected online version.

How this differs from broad inflammation claims

An editorial discussing incretin therapies and residual inflammation in biologic-treated psoriasis raises a broader research question. It is commentary, not an additional randomized test of tirzepatide monotherapy.³

The combination trial also cannot be generalized to lupus, all autoimmune diseases or every psoriasis subtype. A plausible inflammation mechanism is a starting point for research; a specific clinical trial supports a narrower treatment claim. Our evidence guide explains why those levels of evidence need separate treatment.

Safety and eligibility still matter

Gastrointestinal events were more frequent with the combination in the trial. Current Zepbound prescribing information includes important contraindications and precautions, including the thyroid C-cell tumor warning, serious hypersensitivity and severe gastrointestinal reactions. Psoriasis is not listed as a Zepbound indication.¹⁴

The absence of a new safety concern in a study does not guarantee that a combination is appropriate for every person. Your clinician should review existing medicines, symptoms and reasons you may not be eligible before adding treatment. Our Zepbound side-effects guide covers the approved product's safety information in more detail.

Questions for a coordinated appointment

Ask whether you meet an approved weight-management indication independently of your psoriasis, whether your current skin treatment is working and whether the combination studied resembles your proposed plan. Also ask how skin response, weight, adverse effects and adherence would be monitored together.

The evidence offers a reason to address obesity alongside psoriasis care. It does not supply a reason to stop a successful biologic or purchase tirzepatide solely on an unqualified anti-inflammatory claim.